Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -657.69% is 388% below its 5-year average of -134.82%, near the low end of its 5-year range (-674.50%–-26.68%).
As of the fiscal period ended Tuesday, June 30, 2026. 43.74% below its 12-month average of -457.54%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -657.69%.
RETURN ON EQUITY (ROE)
-657.69%
RETURN ON EQUITY (ROE) AVG TTM
-457.54%
RETURN ON EQUITY (ROE) AVG 3Y
-293.99%
RETURN ON EQUITY (ROE) AVG 5Y
-134.82%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
-43.74%
CURRENT VS 3Y AVG
-123.71%
CURRENT VS 5Y AVG
-387.81%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-42.01%
median of 745 covered companies
CURRENT VS SECTOR MEDIAN
-1465.55%
vs the sector median at left
iSpecimen Inc.
Market Cap
$2.77M
Return on Equity (ROE)
-657.69%
TTM Avg
-457.54%
3Y Avg
-293.99%
5Y Avg
-134.82%
Market Cap
$2.84M
Return on Equity (ROE)
-6.54%
TTM Avg
-12.86%
3Y Avg
-15.03%
5Y Avg
-0.76%
Market Cap
$2.62M
Return on Equity (ROE)
N/A
TTM Avg
-419.35%
3Y Avg
-396.40%
5Y Avg
-293.00%
Market Cap
$2.54M
Return on Equity (ROE)
-402.92%
TTM Avg
-276.14%
3Y Avg
-197.40%
5Y Avg
-116.89%
Market Cap
$3.01M
Return on Equity (ROE)
-365.43%
TTM Avg
-2048.73%
3Y Avg
-1082.52%
5Y Avg
-614.77%
Market Cap
$3.04M
Return on Equity (ROE)
N/A
TTM Avg
-236.13%
3Y Avg
-104.67%
5Y Avg
-48.54%
Market Cap
$2.50M
Return on Equity (ROE)
-391.26%
TTM Avg
-355.49%
3Y Avg
-474.62%
5Y Avg
-295.97%
Market Cap
$3.06M
Return on Equity (ROE)
-106.79%
TTM Avg
-210.00%
3Y Avg
-362.69%
5Y Avg
1766.26%
Market Cap
$2.47M
Return on Equity (ROE)
-554.01%
TTM Avg
-109.66%
3Y Avg
1542.76%
5Y Avg
920.25%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| iSpecimen Inc. (ISPC) | $2.77M | -657.69% | -457.54% | -293.99% | -134.82% |
| Universe Pharmaceuticals Inc. (UPC)vs › | $2.84M | -6.54% | -12.86% | -15.03% | -0.76% |
| Nuwellis, Inc. (NUWE)vs › | $2.62M | N/A | -419.35% | -396.40% | -293.00% |
| bioAffinity Technologies, Inc. (BIAF)vs › | $2.54M | -402.92% | -276.14% | -197.40% | -116.89% |
| BioRestorative Therapies, Inc. (BRTX)vs › | $3.01M | -365.43% | -2048.73% | -1082.52% | -614.77% |
| Adagio Medical Holdings, Inc. (ADGM)vs › | $3.04M | N/A | -236.13% | -104.67% | -48.54% |
| FibroBiologics, Inc. Common Stock (FBLG)vs › | $2.50M | -391.26% | -355.49% | -474.62% | -295.97% |
| Revelation Biosciences, Inc. (REVB)vs › | $3.06M | -106.79% | -210.00% | -362.69% | 1766.26% |
| Jaguar Health, Inc. (JAGX)vs › | $2.47M | -554.01% | -109.66% | 1542.76% | 920.25% |
| IceCure Medical Ltd (ICCM)vs › | $3.12M | -141.90% | -194.17% | -143.89% | -113.05% |
ROE
-657.7%
ROA
-154.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -657.69% |
| 2025-12-31 | -339.60% |
| 2025-09-30 | -375.34% |
| 2025-03-31 | -674.50% |
| 2024-12-31 | -377.46% |
| 2024-09-30 | -202.01% |
| 2024-06-30 | -167.43% |
| 2024-03-31 | -169.81% |
| 2023-12-31 | -113.95% |
| 2023-09-30 | -80.17% |
| 2023-06-30 | -75.90% |
| 2023-03-31 | -56.89% |
| 2022-12-31 | -50.42% |
| 2022-09-30 | -45.18% |
| 2022-06-30 | -33.97% |
| 2022-03-31 | -26.68% |
| 2021-12-31 | -30.08% |
| 2021-09-30 | -70.34% |
| 2021-06-30 | -76.77% |
